Nxera Pharma to Host Noteworthy R&D Day Event
Nxera Pharma Co., Ltd. is gearing up for an informative R&D Day where key leaders will share significant updates about their research and development efforts. This virtual event is scheduled for November, aiming to provide insights into the company's innovative projects and advancements in medicine.
Event Details and Agenda
The R&D Day will unfold on a Wednesday in November, commencing at 16:30 JST. Participants can join through the Zoom webinar platform. For those interested, early registration is encouraged.
Presenters of the Day
A stellar lineup of presenters is set to take the stage, including:
- Chris Cargill, President and CEO
- Dr. Matt Barnes, Executive Officer and President of Nxera Pharma UK
- Dr. Makoto Sugita, Chief Medical Officer and President of Nxera Pharma Japan
- Hironoshin Nomura, Chief Financial Officer
What to Expect from the Presentations
Attendees can look forward to the presentation slides, which will be accessible prior to the event. The details will be officially posted on the investor section of Nxera's website, keeping stakeholders informed and engaged.
Understanding Nxera Pharma
Nxera Pharma, previously known as Sosei Heptares, is a pioneering biopharmaceutical company dedicated to developing new specialty medicines tailored for patients with critical unmet healthcare needs. With an impressive pipeline of active programs, the company is steadfast in its mission to innovate across various medical fields.
Product and Research Pipeline
The company is actively commercializing several products within Japan and has an impressive pipeline boasting over 30 programs ranging from early discovery stages to late clinical phases. This pipeline strategically targets significant gaps within rapidly expanding sectors, including neurology, immunology, and metabolic disorders.
Global Presence and Workforce
Nxera proudly houses a dedicated workforce of over 350 professionals located across essential hubs: Tokyo, Osaka, London, Cambridge, Basel, and Seoul. This global footprint allows Nxera to collaborate with some of the leading pharmaceutical and biotech companies worldwide.
A Commitment to Innovation
The company leverages its unique GPCR-targeted structure-based drug discovery NxWave platform, fostering a sustainable source of promising drug candidates. This innovative approach is geared toward creating therapies that are first- or best-in-class, thereby enhancing outcomes for patients across the medical spectrum.
Contact Information
For inquiries, Nxera provides easy access to its media and investor relations team, led by:
- Kentaro Tahara, VP Investor Relations and Corporate Strategy
- Shinichiro Nishishita, VP Investor Relations
- Maya Bennison, Communications Manager
They can be reached at the provided international contact numbers. Additionally, interested parties can connect via email for further communications.
Frequently Asked Questions
What is the purpose of Nxera Pharma's R&D Day?
The R&D Day aims to update stakeholders about the company's ongoing research efforts and showcase innovative approaches to medicine development.
Who will be presenting at the R&D Day?
Key leaders, including the CEO and various executive officers, will share insights during the event.
How can I participate in the R&D Day?
Registration for the virtual event can be done in advance on the company’s website.
What is the significance of Nxera Pharma's pipeline?
The pipeline reflects Nxera's commitment to addressing unmet medical needs with innovative therapeutic options.
How can I contact Nxera Pharma for more information?
Contact information for media and investor relations is available, providing various options for inquiries via phone and email.
